Integrating a Harm Reduction Approach into Clinical Encounters for Buprenorphine Patients

January 10, 2020
Registration


This is a private course and registrations are not being accepted.
 

Target Audience

Primary care providers, clinical behavior health specialists and behavior health directors.

Medication Assisted Treatment ECHO

This interactive web-based program provides essential guidelines and steps to implementing and integrating a successful MAT program into an outpatient primary care setting. The MAT program aims to improve access for patients suffering from opioid use disorder.

  • Diagnosing Opioid Use Disorder
  • Types of medications (naltrexone vs. buprenorphine) and requirements for each (labs, monitoring, etc.)
  • Buprenorphine induction maintenance, relapse and tapering protocols
  • Referral process, clinic flow
  • Opiate withdrawal-treatment
  • Drug screens
  • Controlled substance agreement
  • Multi-party consents
  • Prior authorization requirements for buprenorphine (documentation, barriers, etc.)
  • Clinic and community integration

Purpose

The purpose is to inform clinic members (admin, providers, nursing, etc.) on how to successfully integrate a MAT program into an outpatient primary care setting. The mission is to help centers and clinics set up primary care based MAT to improve access for patients suffering from opioid use disorder across the state of Iowa. 

Learning Objectives

  • Understand the multi-faceted meaning of “Harm Reduction” and move beyond “sterile needles and narcan” in conceptualizing Harm Reduction’s role in MAT services
  • Identify four or more harm reduction strategies that can be applied in clinical encounters  with MAT patients
  • Apply a harm reduction framework to MAT patients in your practice in order to improve patient trust, engagement, and health outcomes. 
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credits
  • 1.00 AOA Category 1­A
  • 1.00 CE Contact Hour(s)
  • 1.00 IBON
Course opens: 
01/10/2020
Course expires: 
01/10/2020
Event starts: 
01/10/2020 - 12:00pm
Event ends: 
01/10/2020 - 1:00pm
Cost:
$0.00
Rating: 
0

Moderator

Gagan Lamba, MA, MS, MBA, CSM 
Behavioral Health Manager, Primary Health Care, Inc.

Relevant to the content of this CME activity, Ms. Lamba and planning committee indicated they have no financial relationships with commercial interest companies to disclose.

Speaker

Sarah Ziegenhorn
Executive Director, Iowa Harm Reduction Coalition

Relevant to the content of this CME activity, Ms. Ziegenhorn disclosed that she has received grant or research support from Gilead and Merck. 

Accreditation Statements

  • DO: Des Moines University (DMU) is accredited by the American Osteopathic Association (AOA) to provide osteopathic continuing medical education for physicians. DMU designates this program for a maximum of 1.0 AOA Category 1-A credits and will report CME and specialty credits commensurate with the extent of the physician’s participation in this activity.
  • MD:  This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Iowa Medical Society (IMS) through the joint providership of Des Moines University (DMU) and Primary Health Care, Inc. DMU is accredited by IMS to provide continuing medical education for physicians. DMU designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • Nurse: Des Moines University is Iowa Board of Nursing approved provider #112. This live activity has been reviewed and approved for 1.0 continuing education contact hour(s). No partial credit awarded.
  • Other healthcare professionals: This live activity is designated for 1.0 AMA PRA Category 1 Credit(s)TM

EDUCATIONAL GRANTS

No commercial interest company provided financial support for this continuing education activity.

DISCLOSURE

Everyone in a position to control the content of this educational activity will disclose to the CME provider and to attendees all relevant financial relationships with any commercial interest. The speaker(s) will disclose if any pharmaceuticals or medical procedures and devices discussed are investigational or unapproved for use by the U.S. Food and Drug Administration (FDA). Determination of educational content and the selection of speakers is the responsibility of the activity director. Firms providing financial support did not have input in these areas.

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition. The content of each presentation does not necessarily reflect the views of Des Moines University.

Available Credit

  • 1.00 AMA PRA Category 1 Credits
  • 1.00 AOA Category 1­A
  • 1.00 CE Contact Hour(s)
  • 1.00 IBON

Price

Cost:
$0.00
Please login or Create an Account to take this course.